We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

When President Donald Trump declared in May that he wanted drug companies to voluntarily cut their prices, few pharmaceutical executives wanted to go first. Now, no one wants to be last – and risk the ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

We recently published 12 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

Health IT’s Legacy and the Road to Responsible AI by Dr. S. Yin Ho is an indispensable book about the current state of health information technology and how responsible AI could reshape our U.S.

Nine large pharma companies have reached agreements with the Trump administration to lower certain drug prices in the U.S. | ...

No one's crossed the finishing line yet, but drug developer Nyrada is leading the Great Biotech Regatta of 2025 with close to ...